November 28, 2016 - By Winifred Garcia
In a report revealed to clients and investors on 28 November, Citigroup has upgraded Horizon Pharma (NASDAQ:HZNP) stock to a “Buy”. HZNP’s old rating was “Neutral”.
Out of 9 analysts covering Horizon Pharma (NASDAQ:HZNP), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. $40 is the highest target while $21 is the lowest. The $28.33 average target is 31.83% above today’s ($21.49) stock price. Horizon Pharma has been the topic of 20 analyst reports since September 9, 2015 according to StockzIntelligence Inc. The company was maintained on Tuesday, August 9 by Citigroup. On Friday, October 9 the stock rating was initiated by Mizuho with “Buy”. The stock has “Underweight” rating given by Morgan Stanley on Thursday, December 3. The rating was upgraded by Morgan Stanley on Monday, July 11 to “Equal-Weight”. The firm has “Buy” rating by Mizuho given on Tuesday, September 13. The firm earned “Market Perform” rating on Friday, September 16 by Cowen & Co. The firm earned “Buy” rating on Monday, October 31 by Mizuho. The company was initiated on Monday, June 6 by Goldman Sachs. The company was maintained on Tuesday, November 8 by Mizuho. The rating was maintained by Mizuho on Tuesday, May 10 with “Buy”.
It is down 32.49% since April 25, 2016 and is uptrending. It has outperformed by 26.48% the S&P500.
Analysts await Horizon Pharma PLC (NASDAQ:HZNP) to report earnings on March, 6. They expect $0.52 EPS, 0.00% or $0.00 from last year’s $0.52 per share. HZNP’s profit will be $83.96M for 10.33 P/E if the $0.52 EPS becomes a reality. After $0.56 actual EPS reported by Horizon Pharma PLC for the previous quarter, Wall Street now forecasts -7.14% negative EPS growth.
Insitutional Activity: The institutional sentiment increased to 1.46 in 2016 Q2. Its up 0.25, from 1.21 in 2016Q1. The ratio improved, as 46 funds sold all Horizon Pharma PLC shares owned while 45 reduced positions. 38 funds bought stakes while 72 increased positions. They now own 135.34 million shares or 2.87% less from 139.33 million shares in 2016Q1.
Citigroup Incorporated accumulated 72,032 shares or 0% of the stock. Parametric Associate has 509,860 shares for 0.01% of their US portfolio. The Montana-based Davidson Inv Advsr has invested 0% in Horizon Pharma PLC (NASDAQ:HZNP). Capital Fund Mngmt Sa has 54,027 shares for 0.01% of their US portfolio. Gilder Gagnon Howe & Ltd Co has 0% invested in the company for 4,709 shares. Kcg Holdings Inc accumulated 31,365 shares or 0.01% of the stock. Lombard Odier Asset Mgmt (Usa) accumulated 350,000 shares or 0.7% of the stock. Comml Bank Of America Corporation De holds 0% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP) for 476,918 shares. Lakeview Capital Partners Ltd accumulated 33,348 shares or 0.33% of the stock. Acadian Asset Mngmt Ltd Llc reported 624 shares or 0% of all its holdings. Vanguard Inc has 0.01% invested in the company for 10.57M shares. Redwood Investments Ltd Limited Liability Company last reported 0.38% of its portfolio in the stock. Manufacturers Life Insur The holds 0% or 108,847 shares in its portfolio. Da Davidson And Com has invested 0% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP). Blackrock Japan Ltd last reported 1,035 shares in the company.
Insider Transactions: Since June 15, 2016, the stock had 0 insider buys, and 2 sales for $500,280 net activity. The insider SHERMAN JEFFREY W sold 2,900 shares worth $58,000. Nohria Virinder sold $442,280 worth of stock.
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The company has a market cap of $3.47 billion. The Firm is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It currently has negative earnings. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
According to Zacks Investment Research, “Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company’s U.S. marketed products are ACTIMMUNEÂ® (interferon gamma-1b), DUEXISÂ® (ibuprofen/famotidine), PENNSAIDÂ® (diclofenac sodium topical solution) 2% w/w, RAYOSÂ® (prednisone) delayed-release tablets and VIMOVOÂ® (naproxen/esomeprazole magnesium). Horizon’s global headquarters are in Dublin, Ireland.”
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, incorporated on December 20, 2011, is a biopharmaceutical company. The Firm is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. The Firm markets approximately nine medicines through its orphan, primary care and rheumatology business units. The Company’s segment focuses on the identification, development, acquisition and commercialization of differentiated and accessible medicines. The Company’s marketed medicines include ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate and caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% w/w, or PENNSAID 2%, RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Firm also developed DUEXIS and RAYOS, known as LODOTRA.
More recent Horizon Pharma PLC (NASDAQ:HZNP) news were published by: Fool.com which released: “Why Horizon Pharma PLC Jumped Higher Today” on November 07, 2016. Also Seekingalpha.com published the news titled: “Horizon Pharma Plc (HZNP) Q3 2016 Results – Earnings Call Transcript” on November 07, 2016. Globenewswire.com‘s news article titled: “Horizon Pharma plc Announces Availability of RAVICTI® (glycerol phenylbutyrate …” with publication date: November 03, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.